AG-50W-X8, H + form) that was allowed to stir for an additional 10 min. The reaction mixture was filtered and the solvents were evaporated for column purification eluting with 10% MeOH in EtOAc. 2 was collected as a white solid in 50% yield (0.063 g, 0.23 mmol). 1 H NMR (500 MHz, CD 3 OD) δ = 7.97
(dd, J 1 = 6.9 Hz, J 2 = 2.3 Hz, 1H), 7.53 (dt, J 1 = 8.6 Hz, 2.3 Hz, 1H), 6.67 (dd, J 1 = 9.2 Hz, J 2 = 1.7 Hz, 1H), 6.34 (dt, J 1 = 6.9 Hz, J 2 = 1. , 5.53; N, 5.13. Found: C, 47.95; H, 5.90 ; N, 4.86.
2-Methyl-4H-pyran-4-one-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside) (4a). The synthesis of
4a was accomplished following the same procedure as that for 2a using 3-hydroxy-2-methyl-4-pyrone (1.0 g, 7.9 mmol), 1-bromo-α-D-glucose tetraacetate (1.3 g, 3.2 mmol) and tetrabutylammonium bromide 173.6, 170.4, 170.1, 170.0, 169.5, 161.2, 153.7, 141.2, 117.2, 99.3, 72.4, 71.7, 71.2, 68.3, 61.5, 20.8, 20.6, 15 
2-Methyl-4H-pyran-4-one-3-β-D-glucopyranoside (4). The synthesis of 4 was accomplished
following the procedure for the synthesis of 2 using 0.15 g (0.33 mmol) of 4a and 0.23 mL (0.99 mmol)
of NaOMe (25% in MeOH) in 10 mL of dry MeOH. 4 was collected as a white solid in 95% yield (0.90 g, 0.31 mmol).
3.23 (m, 1H, CHCH a H b OH), 2.45 (s, 3H, ArCH 3 ).
13 C NMR (125 MHz, CD 3 OD) δ = 175. 9, 163.3, 155.9, 142.3, 116.0, 104.1, 77.2, 76.7, 74.1, 69.7, 61.2, 14.6 193.4, 170.4, 170.1, 170.0, 169.5, 158.3, 149.1, 145.7, 128.9, 98.4, 72.3, 71.7, 71.1, 68.4, 61.4, 21.1, 20.6, 15.8 193.7, 159.3, 150.2, 147.3, 127.8, 102.8, 77.0, 76.5, 74.4, 69.6, 67.6 N-(Biphenyl-4-ylmethyl)-1-hydroxy-6-oxo-1,6-dihydropyridine-2-carboxamide, 1,2-HOPO-2 (7).
This compound was prepared as previously reported ( 170.9, 169.9, 169.8, 169.4, 159.3, 157.7, 143.3, 140.8, 140.7, 138.7, 136.8, 129.1, 128.8, 127.9, 127.4, 127.2, 124.1, 106.9, 101.1, 72.9, 71.6, 69.5, 68.2, 61.4, 43.8, 20.8, 20.6, 20. N-(Biphenyl-4-ylmethyl)-6-oxo-1-(β-D-glucopyranosyloxy)-1,6-dihydropyridine-2-carboxamide (8). 8a (0.086 g, 0.13 mmol) was dissolved in dry MeOH (3 mL) in an ice bath. After stirring at 0 °C for by the addition of a ~100 mg of cation exchange resin (Biorad AG-50W-X8, H + form) which was allowed to stir for an additional 10 minutes. 9, 158.9, 144.6, 140.7, 140.5, 139.7, 136.8, 128.5, 126.9, 126.7, 122.7, 106.6, 105.8, 77.1, 76.3, 72.3, 69.8, 61 UV-Vis Spectroscopy. Absorption spectra of compounds 1-8 were taken on a Perkin-Elmer Lambda 25
UV-visible spectrophotometer. To a 1.0 mL solution at 0.05 -0.06 mM concentration in HEPES buffer (50 mM, pH 7.5) was added β-glucosidase (16 U for compounds 2, 4, and 6, and 100 U for compound 8).
Spectra were monitored over time either at room temperature for compounds 1-7 or at 37 °C for compound 8.
Calculation of K m . To a 1.0 mL solution of 8 in HEPES buffer at 25 µM, 50 µM, 75 µM, 100 µM, and 200 µM was added 100 U of β -glucosidase. Spectra were monitored over 4 h at 37 °C. The concentration of product formed, 1,2-HOPO-2 (7), was determined using the extinction coefficient for 7 calculated at 346 nm (4279 ± 372 M -1 cm -1 ) and was plotted versus time (min). The initial velocity (ν) of each reaction was determined analyzing the linear slope of the first 50 min. The K m value was calculated from the Lineweaver-Burk plot (1/ν vs. 1/[8]) where -1/K m equals the x-intercept ( Figure S10 ).
Acid Stability. To examine the stability of compound 8 towards acid hydrolysis, the absorption spectra of a 0.05 mM solution of 8 in a 0.1 M aqueous solution of HCl was collected. Spectra were collected at room temperature every hour for a 24 h time period. No change in the spectra was observed ( Figure S9 ).
HPLC.
Analytical HPLC was performed on a HP Series 1050 system equipped with a Vydac ® C18
reverse phase column (218TP, 250×4.6 mm, 5 µm). Separation was achieved with a flow rate of 1 mL/min and the following solvents: solvent A is 5% MeOH and 0.1% formic acid in H 2 O and solvent B is 0.1% formic acid in MeOH. Starting with 95% A and 5% B, an isocratic gradient was run for 15 min to a final solvent mixture of 5% A and 95% B, which was held for 5 min before ramping back down to 95% A and 5% B in 2 min and holding for an additional 4 min. Compounds 1-6 were prepared in HEPES buffer (50 mM, pH 7.5) at a concentration of 1.6 mM and compounds 7-8 were prepared at a concentration of 1 mM. Retention times of compounds 1-8 were determined under identical HPLC conditions prior to evaluation of glucose cleavage of the protected compounds.
To evaluate the efficiency of glucose cleavage for the protected ZBGs 2, 4, and 6, 1 mL samples of each compound were made up at a concentration of 1.6 mM in HEPES buffer (50 mM, pH 7.5). To each sample was added 50 U of β-glucosidase (1 U/µL) and incubated at 37 °C. After 1 h, a 400 µL aliquot was collected and filtered through a microcentrifuge filter (30 kDa MWCO, PLTK cellulosic membrane)
to remove β-glucosidase prior to injection on the HPLC. For the full-length inhibitor 8, a 1 mL sample in HEPES buffer at a concentration of 1 mM was incubated at 37 °C with 250 U of β-glucosidase (1 U/µL) for 5 h. A 200 µL aliquot was collected every hour and filtered through a microcentrifuge filter prior to injection on the HPLC. DMSO and diluted in HEPES buffer (50 mM, pH 7.5) to a concentration of 10 mM for 1-2, 40 mM for 3-4, and 1.25 mM for 5-6. Each well contained 20 µL of MMP-9 (0.45 U/mL), inhibitor (10 µL fo 1-6), 5 µL of β-glucosidase (1 U/µL) when used, and buffer for a total volume of 99 µL. These were incubated for 1 h at 37 °C. A control sample containing just β-glucosidase (5 µL at 5 U/µL) with MMP-9 (20 µL)
was also prepared to confirm that the β-glucosidase did not inhibit of MMP-9. The reaction was initiated by the addition of 1 µL (400 µM Figure S5 . HPLC traces of compounds 5 (black) and 6 (red) and compound 6 after incubation with β-glucosidase (50 U, blue) for 1 h. Retention times are 11.21 min for 5 and 6.60 min for 6. Figure S6 . Absorption spectra of the glucose-protected full-length inhibitor 1,2-HOPO-2 (8) (0.05 mM in HEPES buffer) in the presence of β-glucosidase (100 U) at 37 °C monitored every 5 min for 4 h with spectra shown every 10 min. The heavy lines are the initial (dashed) and final (solid) spectra; arrows indicate change in spectra over time. A sample of 1,2-HOPO-2 (7) (~0.05 mM) in HEPES buffer is also shown in blue. 
